Report Detail
Global Neuroendocrine Carcinoma Market Insights, Forecast to 2025
- RnM2716884 |
- 02 January, 2019 |
- Global |
- 116 Pages |
- QYResearch |
- Pharma & Healthcare
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.
The somatostatin analogs segment by treatment type is expected to witness high traction in the coming years.
The global Neuroendocrine Carcinoma market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Neuroendocrine Carcinoma market based on company, product type, end user and key regions.
This report studies the global market size of Neuroendocrine Carcinoma in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neuroendocrine Carcinoma in these regions.
This research report categorizes the global Neuroendocrine Carcinoma market by top players/brands, region, type and end user. This report also studies the global Neuroendocrine Carcinoma market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Novartis
Chiasma
Ipsen
Abbvie
Valeant
Jubilant
Teva
F.Hoffmann-La Roche
Advanced Accelerator
Mateon
Lexicon
Market size by Product
Chemotherapy
Somatostatin Analogs
Targeted Therapy
Market size by End User
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Neuroendocrine Carcinoma market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Neuroendocrine Carcinoma market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Neuroendocrine Carcinoma companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Neuroendocrine Carcinoma submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Neuroendocrine Carcinoma are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neuroendocrine Carcinoma market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Neuroendocrine Carcinoma Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Product
- 1.4.2 Chemotherapy
- 1.4.3 Somatostatin Analogs
- 1.4.4 Targeted Therapy
- 1.5 Market by End User
- 1.5.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinics
- 1.5.4 Oncology Centres
- 1.5.5 Ambulatory Surgery Centres
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Neuroendocrine Carcinoma Market Size
- 2.1.1 Global Neuroendocrine Carcinoma Revenue 2014-2025
- 2.1.2 Global Neuroendocrine Carcinoma Sales 2014-2025
- 2.2 Neuroendocrine Carcinoma Growth Rate by Regions
- 2.2.1 Global Neuroendocrine Carcinoma Sales by Regions
- 2.2.2 Global Neuroendocrine Carcinoma Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Neuroendocrine Carcinoma Sales by Manufacturers
- 3.1.1 Neuroendocrine Carcinoma Sales by Manufacturers
- 3.1.2 Neuroendocrine Carcinoma Sales Market Share by Manufacturers
- 3.1.3 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)
- 3.2 Neuroendocrine Carcinoma Revenue by Manufacturers
- 3.2.1 Neuroendocrine Carcinoma Revenue by Manufacturers (2014-2019)
- 3.2.2 Neuroendocrine Carcinoma Revenue Share by Manufacturers (2014-2019)
- 3.3 Neuroendocrine Carcinoma Price by Manufacturers
- 3.4 Neuroendocrine Carcinoma Manufacturing Base Distribution, Product Types
- 3.4.1 Neuroendocrine Carcinoma Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Neuroendocrine Carcinoma Product Type
- 3.4.3 Date of International Manufacturers Enter into Neuroendocrine Carcinoma Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Neuroendocrine Carcinoma Sales by Product
- 4.2 Global Neuroendocrine Carcinoma Revenue by Product
- 4.3 Neuroendocrine Carcinoma Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Neuroendocrine Carcinoma Breakdown Data by End User
6 North America
- 6.1 North America Neuroendocrine Carcinoma by Countries
- 6.1.1 North America Neuroendocrine Carcinoma Sales by Countries
- 6.1.2 North America Neuroendocrine Carcinoma Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Neuroendocrine Carcinoma by Product
- 6.3 North America Neuroendocrine Carcinoma by End User
7 Europe
- 7.1 Europe Neuroendocrine Carcinoma by Countries
- 7.1.1 Europe Neuroendocrine Carcinoma Sales by Countries
- 7.1.2 Europe Neuroendocrine Carcinoma Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Neuroendocrine Carcinoma by Product
- 7.3 Europe Neuroendocrine Carcinoma by End User
8 Asia Pacific
- 8.1 Asia Pacific Neuroendocrine Carcinoma by Countries
- 8.1.1 Asia Pacific Neuroendocrine Carcinoma Sales by Countries
- 8.1.2 Asia Pacific Neuroendocrine Carcinoma Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Neuroendocrine Carcinoma by Product
- 8.3 Asia Pacific Neuroendocrine Carcinoma by End User
9 Central & South America
- 9.1 Central & South America Neuroendocrine Carcinoma by Countries
- 9.1.1 Central & South America Neuroendocrine Carcinoma Sales by Countries
- 9.1.2 Central & South America Neuroendocrine Carcinoma Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Neuroendocrine Carcinoma by Product
- 9.3 Central & South America Neuroendocrine Carcinoma by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Neuroendocrine Carcinoma by Countries
- 10.1.1 Middle East and Africa Neuroendocrine Carcinoma Sales by Countries
- 10.1.2 Middle East and Africa Neuroendocrine Carcinoma Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Neuroendocrine Carcinoma by Product
- 10.3 Middle East and Africa Neuroendocrine Carcinoma by End User
11 Company Profiles
- 11.1 Pfizer
- 11.1.1 Pfizer Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Pfizer Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Pfizer Neuroendocrine Carcinoma Products Offered
- 11.1.5 Pfizer Recent Development
- 11.2 Novartis
- 11.2.1 Novartis Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Novartis Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Novartis Neuroendocrine Carcinoma Products Offered
- 11.2.5 Novartis Recent Development
- 11.3 Chiasma
- 11.3.1 Chiasma Company Details
- 11.3.2 Company Business Overview
- 11.3.Chiasma Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Chiasma Neuroendocrine Carcinoma Products Offered
- 11.3.5 Chiasma Recent Development
- 11.4 Ipsen
- 11.4.1 Ipsen Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Ipsen Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Ipsen Neuroendocrine Carcinoma Products Offered
- 11.4.5 Ipsen Recent Development
- 11.5 Abbvie
- 11.5.1 Abbvie Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Abbvie Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Abbvie Neuroendocrine Carcinoma Products Offered
- 11.5.5 Abbvie Recent Development
- 11.6 Valeant
- 11.6.1 Valeant Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Valeant Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Valeant Neuroendocrine Carcinoma Products Offered
- 11.6.5 Valeant Recent Development
- 11.7 Jubilant
- 11.7.1 Jubilant Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Jubilant Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Jubilant Neuroendocrine Carcinoma Products Offered
- 11.7.5 Jubilant Recent Development
- 11.8 Teva
- 11.8.1 Teva Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Teva Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Teva Neuroendocrine Carcinoma Products Offered
- 11.8.5 Teva Recent Development
- 11.9 F.Hoffmann-La Roche
- 11.9.1 F.Hoffmann-La Roche Company Details
- 11.9.2 Company Business Overview
- 11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Products Offered
- 11.9.5 F.Hoffmann-La Roche Recent Development
- 11.10 Advanced Accelerator
- 11.10.1 Advanced Accelerator Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Advanced Accelerator Neuroendocrine Carcinoma Products Offered
- 11.10.5 Advanced Accelerator Recent Development
- 11.11 Mateon
- 11.12 Lexicon
12 Future Forecast
- 12.1 Neuroendocrine Carcinoma Market Forecast by Regions
- 12.1.1 Global Neuroendocrine Carcinoma Sales Forecast by Regions 2019-2025
- 12.1.2 Global Neuroendocrine Carcinoma Revenue Forecast by Regions 2019-2025
- 12.2 Neuroendocrine Carcinoma Market Forecast by Product
- 12.2.1 Global Neuroendocrine Carcinoma Sales Forecast by Product 2019-2025
- 12.2.2 Global Neuroendocrine Carcinoma Revenue Forecast by Product 2019-2025
- 12.3 Neuroendocrine Carcinoma Market Forecast by End User
- 12.4 North America Neuroendocrine Carcinoma Forecast
- 12.5 Europe Neuroendocrine Carcinoma Forecast
- 12.6 Asia Pacific Neuroendocrine Carcinoma Forecast
- 12.7 Central & South America Neuroendocrine Carcinoma Forecast
- 12.8 Middle East and Africa Neuroendocrine Carcinoma Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Neuroendocrine Carcinoma Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Neuroendocrine Carcinoma . Industry analysis & Market Report on Neuroendocrine Carcinoma is a syndicated market report, published as Global Neuroendocrine Carcinoma Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Neuroendocrine Carcinoma market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
